Arthritis4Cure is advancing a differentiated pipeline of precision immunotherapies targeting the drivers of autoimmune diseases.

Our platform combines disease-specific autoantigen targeting with immune effector mechanisms to address the drivers of chronic inflammation while preserving broader immune function. 

The company’s lead program, A4C-001, is focused on rheumatoid arthritis and is currently advancing through preclinical development toward first-in-human clinical studies.

Beyond rheumatoid arthritis, the platform has the potential to expand into multiple autoimmune indications characterized by pathogenic autoantibodies and autoreactive immune cells.